Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOPHYL-225 vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/m L.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Terminal half-life: 3–12 hours (adults); shorter (1–5 hours) in children and smokers; prolonged in hepatic cirrhosis, heart failure, or elderly. Steady-state achieved in 1–2 days.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Primarily hepatic via CYP1A2 and to a lesser extent CYP2E1, CYP3A4; exhibits nonlinear pharmacokinetics at high concentrations.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal: 10% unchanged; hepatic metabolism (CYP1A2, CYP3A4) accounts for ~90% of elimination, with metabolites (e.g., 3-methylxanthine, 1,3-dimethyluric acid) excreted renally.
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 40% bound to albumin (primarily); binding is concentration-independent.
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.3–0.7 L/kg; distributes freely into tissues and breast milk; Vd reflects moderate tissue penetration and rapid equilibration.
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: 100% (complete absorption); bioavailability not significantly affected by food. Rectal: ~80% (variable due to absorption site).
Oral: 40-50%; Inhalation: 20-30%
No specific GFR-based adjustment required; monitor serum theophylline levels as renal impairment may affect clearance.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 50-75%; Child-Pugh C: reduce dose by 75-90% or consider alternative. Frequent serum level monitoring is mandatory.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Initial: 5 mg/kg orally every 6 hours; titrate based on serum levels. Usual maintenance: 10-20 mg/kg/day divided every 6 hours. Not recommended under 1 year without specialist advice.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Start at lower dose (e.g., 112.5 mg every 6 hours) due to decreased clearance; titrate slowly with close serum level monitoring. Target lower end of therapeutic range (8-12 mcg/m L) if tolerated.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
No FDA black box warning.
No FDA black box warning.
Narrow therapeutic index; serum levels must be monitored (target 5-15 mcg/m L),Risk of seizure and cardiac arrhythmias at toxic levels,Increased seizure risk in patients with preexisting seizure disorders,Use with caution in liver impairment, congestive heart failure, and elderly,May cause tachycardia, palpitations, and exacerbation of arrhythmias
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to theophylline or other xanthines (e.g., caffeine, theobromine),Pre-existing cardiac arrhythmias, particularly tachyarrhythmias,Active seizure disorder,Severe hepatic impairment
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid excessive caffeine from coffee, tea, cola, and chocolate which can increase side effects. High-protein, low-carbohydrate diets may increase theophylline clearance. Charcoal-broiled foods and cruciferous vegetables (e.g., broccoli, cabbage) may induce metabolism and lower levels.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Theophylline crosses the placenta. First trimester: No clear association with major malformations in human studies, but limited data. Second/third trimester: Risk of fetal tachycardia, jitteriness, and irritability at high maternal serum levels (toxicity). May cause transient neonatal withdrawal symptoms (apnea, vomiting) if used near term.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Theophylline is excreted into breast milk; M/P ratio approximately 0.7. Infant serum levels can reach therapeutic levels, especially with maternal doses >10 mg/kg/day. Use with caution; monitor infant for signs of irritability or insomnia. AAP considers compatible with breastfeeding but observe infant.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Clearance of theophylline decreases in pregnancy, especially in third trimester, leading to prolonged half-life. Dose reduction may be required to avoid toxicity; monitor serum levels closely. Typically, total daily dose may need reduction by 20-30% in late pregnancy. Postpartum, clearance normalizes quickly, necessitating dose increase.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Theophylline has a narrow therapeutic index; target serum concentration is 5-15 mcg/m L. Monitor levels due to variable clearance. CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., rifampin, smoking) significantly alter levels. Use with caution in hepatic impairment, heart failure, and elderly. Slow IV infusion over 20-30 minutes for loading dose to avoid hypotension and arrhythmias. Caffeine and theobromine (chocolate) can increase toxicity risk.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take the medication exactly as prescribed; do not change dose without consulting your doctor.,Avoid smoking and limit caffeine intake (coffee, tea, cola, chocolate) as they can affect drug levels.,Report symptoms of toxicity immediately: nausea, vomiting, diarrhea, restlessness, insomnia, rapid heartbeat, or seizures.,Do not crush or chew sustained-release tablets; swallow whole.,Keep all appointments for blood tests to monitor theophylline levels.,Inform your doctor of all medications you are taking, especially antibiotics, seizure medicines, and heart medications.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOPHYL-225 vs AEROLATE III, answered by our medical review team.
THEOPHYL-225 is a Bronchodilator that works by Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular c AMP levels, and antagonizes adenosine receptors (A1, A2). This results in bronchodilation, reduced airway inflammation, and enhanced diaphragmatic contractility.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOPHYL-225 and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOPHYL-225 is: 225 mg orally every 6 hours; adjust based on serum theophylline levels to maintain therapeutic range 10-20 mcg/m L.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOPHYL-225 and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOPHYL-225 is classified as Category C. Theophylline crosses the placenta. First trimester: No clear association with major malformations in human studies, but limited data. Second/third trimester: Risk of fetal tachycar. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.